Skip to main content
Clinical Trials/NCT01914120
NCT01914120
Unknown
Not Applicable

A Multicenter, Observational, Phase III Clinical Study: the Quality of Life Assessment of Lung Cancer Patients in China.

Sun Yat-sen University1 site in 1 country3,000 target enrollmentNovember 2012
ConditionsLung Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
Sun Yat-sen University
Enrollment
3000
Locations
1
Primary Endpoint
the change of quality of life
Last Updated
10 years ago

Overview

Brief Summary

The goal of this study is assess the quality of life of advanced non-small cell lung cancer (NSCLC) patients who are undergoing first-line chemotherapy, analyze the current status and tendency of quality of life (QOL). The method is to use the Functional Assessment of Cancer Therapy-Lung (FACT-L) scales, assess the quality of life before the chemotherapy, after 1st cycle of chemotherapy and after 2nd cycle. After 3 time-points, investigators analyze all the subscales and constructs of FACT-L. The assumption is the quality of life will be better after 2 cycle of chemotherapy.

Detailed Description

1. Lung cancer is the most deadly cancer in the world, 85% lung cancer are non-small cell lung cancer (NSCLC). The quality of life of NSCLC patients become more and more important, because of most NSCLC is incurable. 2. The recruitment will take place in 20 center all over the country and 500 patients will enrolled.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
June 2017
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Sun Yat-sen University
Responsible Party
Principal Investigator
Principal Investigator

Li Zhang

Profressor

Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

  • age: \>18 and \<75 years old
  • pathological or cytological diagnosis confirmed advanced non-small cell lung cancer
  • Eastern Cooperative Oncology Group Performance Status: 0-2
  • have never receive any kind of anti-cancer chemotherapy
  • agree to regularly assessment of quality of life
  • sign the informed consent form

Exclusion Criteria

  • Currently attending any antitumor drug clinical trials
  • Pregnancy or breast-feeding women
  • Currently receiving anti-tumor chemotherapy, or received any antitumor chemotherapy previously.
  • not suitable to participate in this test

Outcomes

Primary Outcomes

the change of quality of life

Time Frame: Change from baseline quality of life at 6 weeks

use Functional Assessment of Cancer Therapy-Lung (FACT-L) scales assess the quality of life to all subjects. before chemotherapy; after 1st chemotherapy; after 2nd chemotherapy;

Secondary Outcomes

  • overall survival(24 months)

Study Sites (1)

Loading locations...

Similar Trials